Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1183/13993003.02425-2016 http://scihub22266oqcxt.onion/10.1183/13993003.02425-2016 C5898946!5898946 !28889107     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28889107 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Eur+Respir+J 2017 ; 50 (3 ): ä Nephropedia Template TP {{tp|p=28889107 |t=2017. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors |pdf=|usr=}}{{28889107 }} gab.com Text RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors JO: Eur Respir J http://www.kidney.de/pget.php?&tw=1&pmid=28889107 #FOAvip A proportion of pulmonary arterial hypertension (PAH) patients do not reach treatment goals with phosphodiesterase-5 inhibitors (PDE5i). RESPITE investigated the safety, feasibility and benefit of switching from PDE5i to riociguat in these patients.RESPITE was a 24-week, open-label, multicentre, uncontrolled study. Patients in World Health Organization (WHO) functional class (FC) III, with 6-min walking distance (6MWD) 165-440?m, cardiac index <3.0?L·min(-1)·m(-2) and pulmonary vascular resistance >400?dyn·s·cm(-5) underwent a 1-3?day PDE5i treatment-free period before receiving riociguat adjusted up to 2.5?mg maximum t.i.d Exploratory end-points included change in 6MWD, WHO FC, N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and safety.Of 61 patients enrolled, 51 (84%) completed RESPITE. 50 (82%) were receiving concomitant endothelin receptor antagonists. At week 24, mean±sd 6MWD had increased by 31±63?m, NT-proBNP decreased by 347±1235?pg·mL(-1) and WHO FC improved in 28 patients (54%). 32 patients (52%) experienced study drug-related adverse events and 10 (16%) experienced serious adverse events (2 (3%) study drug-related, none during the PDE5i treatment-free period). Six patients (10%) experienced clinical worsening, including death in two (not study drug-related).In conclusion, selected patients with PAH may benefit from switching from PDE5i to riociguat, but this strategy needs to be further studied. Twit Text FOAVip RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors ????Eur Respir J http://www.kidney.de/pget.php?&tw=1&pmid=28889107 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28889107 #FOAvip English Wikipedia <ref>{{Cite pmid|28889107 }}</ref> RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors #MMPMID28889107 Hoeper MM ; Simonneau G ; Corris PA ; Ghofrani HA ; Klinger JR ; Langleben D ; Naeije R ; Jansa P ; Rosenkranz S ; Scelsi L ; Grünig E ; Vizza CD ; Chang M ; Colorado P ; Meier C ; Busse D ; Benza RL Eur Respir J 2017[Sep]; 50 (3 ): ä PMID28889107 show ga A proportion of pulmonary arterial hypertension (PAH) patients do not reach treatment goals with phosphodiesterase-5 inhibitors (PDE5i). RESPITE investigated the safety, feasibility and benefit of switching from PDE5i to riociguat in these patients.RESPITE was a 24-week, open-label, multicentre, uncontrolled study. Patients in World Health Organization (WHO) functional class (FC) III, with 6-min walking distance (6MWD) 165-440?m, cardiac index <3.0?L·min(-1)·m(-2) and pulmonary vascular resistance >400?dyn·s·cm(-5) underwent a 1-3?day PDE5i treatment-free period before receiving riociguat adjusted up to 2.5?mg maximum t.i.d Exploratory end-points included change in 6MWD, WHO FC, N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and safety.Of 61 patients enrolled, 51 (84%) completed RESPITE. 50 (82%) were receiving concomitant endothelin receptor antagonists. At week 24, mean±sd 6MWD had increased by 31±63?m, NT-proBNP decreased by 347±1235?pg·mL(-1) and WHO FC improved in 28 patients (54%). 32 patients (52%) experienced study drug-related adverse events and 10 (16%) experienced serious adverse events (2 (3%) study drug-related, none during the PDE5i treatment-free period). Six patients (10%) experienced clinical worsening, including death in two (not study drug-related).In conclusion, selected patients with PAH may benefit from switching from PDE5i to riociguat, but this strategy needs to be further studied. |Adolescent [MESH] |Adult [MESH] |Aged [MESH] |Antihypertensive Agents/adverse effects/*therapeutic use [MESH] |Endothelin Receptor Antagonists/therapeutic use [MESH] |Europe [MESH] |Female [MESH] |Humans [MESH] |Hypertension, Pulmonary/*drug therapy/mortality/*physiopathology [MESH] |Male [MESH] |Middle Aged [MESH] |Natriuretic Peptide, Brain/blood [MESH] |North America [MESH] |Peptide Fragments/blood [MESH] |Phosphodiesterase 5 Inhibitors/therapeutic use [MESH] |Prospective Studies [MESH] |Pyrazoles/adverse effects/*therapeutic use [MESH] |Pyrimidines/adverse effects/*therapeutic use [MESH] |Severity of Illness Index [MESH] |Treatment Outcome [MESH] |Vascular Resistance/drug effects [MESH] |Walk Test [MESH] |World Health Organization [MESH]RESPITE: switching to riociguat in pulmonary arterial hypertension pat(epmc).pdf DeepDyve Pubget Overpricing